Zipalertinib (CLN-081)

Name: Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Generic, brand name and therapeutic class of product
Published: 2026-09-14T15:39:06-04:00

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417

Manufacturer: Taiho Oncology
Regulatory submission: NDA submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

3 evidence topics · 3 sources

Manufacturer: Taiho Oncology

“Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc.” (opens the source at this quote in a new tab)

Manufacturer name

“Taiho Oncology, Inc.” (opens the source at this quote in a new tab)
“Taiho Pharmaceutical Co., Ltd.” (opens the source at this quote in a new tab)
“Cullinan Therapeutics, Inc.” (opens the source at this quote in a new tab)

Unapproved product name

“Zipalertinib (development code: CLN-081/TAS6417)” (opens the source at this quote in a new tab)